applied IMC analyses to post-neoadjuvant treatment tumor samples of patients with hepatocellular carcinomas treated by the combination of cabozantinib (tyrosine kinase inhibitor) and nivolumab (anti-PD-1 ICI) to point that samples of responders contained TLS and higher abundance of several immune cells as CD4+ and CD8+ T cells but also higher interactions between the different immune cells. This evidence concerns the gene CD8A and neoplasm.